About the Special Issue

Metabolic-Associated Steatotic Liver Disease (MASLD) has emerged as one of the most prevalent and concerning liver disorders globally. Characterized by the accumulation of fat in liver cells, MASLD is closely associated with metabolic syndrome, obesity, type 2 diabetes, and dyslipidemia. The pathogenesis of MASLD is multifactorial, involving a complex interplay of genetic, environmental, and lifestyle factors. Among these, the role of gut microbiota has gained significant attention in recent years.

The human gut harbors a vast and diverse community of microorganisms that play a crucial role in maintaining metabolic homeostasis and overall health. Alterations in the composition and function of gut microbiota, known as dysbiosis, have been linked to various metabolic disorders, including MASLD. Emerging evidence suggests that gut microbiota can influence liver health through multiple mechanisms, including modulation of inflammation, regulation of bile acid metabolism, production of short-chain fatty acids, and interaction with the host's immune system.

This special issue aims to explore the intricate relationship between gut microbiota and MASLD, focusing on both the pathogenesis and potential management strategies. By bringing together cutting-edge research and expert reviews, we seek to provide a comprehensive overview of current knowledge and highlight future directions for research and clinical practice. Topics covered in this issue include the mechanisms by which gut microbiota contribute to MASLD development, the impact of diet and probiotics on gut-liver axis, and novel therapeutic approaches targeting the gut microbiome.

Keywords: Gut Microbiota; Metabolic-Associated Steatotic Liver Disease (MASLD); Liver Health; Dysbiosis; Metabolic Syndrome; Inflammation; Bile Acid Metabolism; Short-Chain Fatty Acids; Probiotics; Gut-Liver Axis

Call for Papers